Pfizer Limited (PFIZER) - Net Assets
Based on the latest financial reports, Pfizer Limited (PFIZER) has net assets worth Rs42.03 Billion INR (≈ $454.53 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Rs49.22 Billion ≈ $532.28 Million USD) and total liabilities (Rs7.19 Billion ≈ $77.75 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Pfizer Limited (PFIZER) tangible equity ratio to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Rs42.03 Billion |
| % of Total Assets | 85.39% |
| Annual Growth Rate | 12.73% |
| 5-Year Change | 46.73% |
| 10-Year Change | 73.75% |
| Growth Volatility | 45.63 |
Pfizer Limited - Net Assets Trend (2005–2026)
This chart illustrates how Pfizer Limited's net assets have evolved over time, based on quarterly financial data. See defensive interval ratio of Pfizer Limited to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Pfizer Limited (2005–2026)
The table below shows the annual net assets of Pfizer Limited from 2005 to 2026. For live valuation and market cap data, see Pfizer Limited (PFIZER) market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2026-03-31 | Rs42.03 Billion ≈ $454.53 Million |
-0.34% |
| 2025-03-31 | Rs42.17 Billion ≈ $456.10 Million |
+17.30% |
| 2024-03-31 | Rs35.96 Billion ≈ $388.84 Million |
+12.10% |
| 2023-03-31 | Rs32.07 Billion ≈ $346.86 Million |
+11.97% |
| 2022-03-31 | Rs28.64 Billion ≈ $309.78 Million |
+19.70% |
| 2021-03-31 | Rs23.93 Billion ≈ $258.80 Million |
-29.52% |
| 2020-03-31 | Rs33.95 Billion ≈ $367.21 Million |
+12.76% |
| 2019-03-31 | Rs30.11 Billion ≈ $325.66 Million |
+12.23% |
| 2018-03-31 | Rs26.83 Billion ≈ $290.18 Million |
+10.93% |
| 2017-03-31 | Rs24.19 Billion ≈ $261.59 Million |
+14.21% |
| 2016-03-31 | Rs21.18 Billion ≈ $229.05 Million |
+7.35% |
| 2015-03-31 | Rs19.73 Billion ≈ $213.37 Million |
+199.66% |
| 2014-03-31 | Rs6.58 Billion ≈ $71.20 Million |
-61.14% |
| 2013-03-31 | Rs16.94 Billion ≈ $183.25 Million |
+29.87% |
| 2012-03-31 | Rs13.05 Billion ≈ $141.10 Million |
+12.14% |
| 2011-03-31 | Rs11.63 Billion ≈ $125.82 Million |
+17.01% |
| 2010-03-31 | Rs9.94 Billion ≈ $107.53 Million |
+10.35% |
| 2009-03-31 | Rs9.01 Billion ≈ $97.45 Million |
+38.69% |
| 2008-03-31 | Rs6.50 Billion ≈ $70.26 Million |
+47.75% |
| 2007-03-31 | Rs4.40 Billion ≈ $47.56 Million |
+16.97% |
| 2006-03-31 | Rs3.76 Billion ≈ $40.66 Million |
+10.73% |
| 2005-03-31 | Rs3.40 Billion ≈ $36.72 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Pfizer Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 100.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (March 2026)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | Rs457.50 Million | 1.09% |
| Other Components | Rs41.57 Billion | 98.91% |
| Total Equity | Rs42.03 Billion | 100.00% |
Pfizer Limited Competitors by Market Cap
The table below lists competitors of Pfizer Limited ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Youngone
KO:111770
|
$2.25 Billion |
|
HeiLongJiang Kingland Technology Co Ltd
SHE:000711
|
$2.25 Billion |
|
BW LPG Limited
F:BW9
|
$2.25 Billion |
|
Hawaiian Electric Industries Inc
NYSE:HE
|
$2.25 Billion |
|
Südzucker AG
F:SZU
|
$2.25 Billion |
|
P/F Bakkafrost
F:6BF
|
$2.24 Billion |
|
Iluka Resources Limited
F:ILZ
|
$2.24 Billion |
|
XiAn Shaangu Power Co Ltd
SHG:601369
|
$2.24 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Pfizer Limited's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2025 to 2026, total equity changed from 42,174,100,000 to 42,029,000,000, a change of -145,100,000 (-0.3%).
- Net income of 7,224,300,000 contributed positively to equity growth.
- Dividend payments of 7,516,400,000 reduced retained earnings.
- Other comprehensive income decreased equity by 4,151,300,000.
- Other factors increased equity by 4,298,300,000.
Equity Change Factors (2025 to 2026)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Rs7.22 Billion | +17.19% |
| Dividends Paid | Rs7.52 Billion | -17.88% |
| Other Comprehensive Income | Rs-4.15 Billion | -9.88% |
| Other Changes | Rs4.30 Billion | +10.23% |
| Total Change | Rs- | -0.34% |
Book Value vs Market Value Analysis
This analysis compares Pfizer Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 4.94x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 39.90x to 4.94x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2005-03-31 | Rs113.78 | Rs4539.30 | x |
| 2006-03-31 | Rs125.99 | Rs4539.30 | x |
| 2007-03-31 | Rs135.96 | Rs4539.30 | x |
| 2008-03-31 | Rs217.73 | Rs4539.30 | x |
| 2009-03-31 | Rs301.96 | Rs4539.30 | x |
| 2010-03-31 | Rs333.21 | Rs4539.30 | x |
| 2011-03-31 | Rs389.88 | Rs4539.30 | x |
| 2012-03-31 | Rs437.21 | Rs4539.30 | x |
| 2013-03-31 | Rs567.81 | Rs4539.30 | x |
| 2014-03-31 | Rs143.92 | Rs4539.30 | x |
| 2015-03-31 | Rs431.26 | Rs4539.30 | x |
| 2016-03-31 | Rs462.95 | Rs4539.30 | x |
| 2017-03-31 | Rs528.72 | Rs4539.30 | x |
| 2018-03-31 | Rs586.49 | Rs4539.30 | x |
| 2019-03-31 | Rs658.22 | Rs4539.30 | x |
| 2020-03-31 | Rs742.18 | Rs4539.30 | x |
| 2021-03-31 | Rs523.07 | Rs4539.30 | x |
| 2022-03-31 | Rs626.10 | Rs4539.30 | x |
| 2023-03-31 | Rs701.08 | Rs4539.30 | x |
| 2024-03-31 | Rs785.94 | Rs4539.30 | x |
| 2025-03-31 | Rs921.88 | Rs4539.30 | x |
| 2026-03-31 | Rs918.73 | Rs4539.30 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Pfizer Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 17.19%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 28.67%
- • Asset Turnover: 0.51x
- • Equity Multiplier: 1.17x
- Recent ROE (17.19%) is below the historical average (18.74%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2005 | 13.13% | 7.52% | 1.14x | 1.54x | Rs106.34 Million |
| 2006 | 18.81% | 11.23% | 1.09x | 1.53x | Rs331.37 Million |
| 2007 | 26.21% | 15.35% | 1.07x | 1.59x | Rs657.62 Million |
| 2008 | 52.33% | 48.71% | 0.80x | 1.34x | Rs2.75 Billion |
| 2009 | 33.25% | 43.95% | 0.62x | 1.22x | Rs2.09 Billion |
| 2010 | 13.77% | 17.72% | 0.64x | 1.21x | Rs374.50 Million |
| 2011 | 14.52% | 19.25% | 0.63x | 1.19x | Rs525.32 Million |
| 2012 | 12.99% | 15.51% | 0.69x | 1.21x | Rs389.73 Million |
| 2013 | 29.70% | 53.08% | 0.46x | 1.22x | Rs3.34 Billion |
| 2014 | 10.60% | 3.77% | 2.00x | 1.40x | Rs39.78 Million |
| 2015 | 3.54% | 3.77% | 0.71x | 1.32x | Rs-1.27 Billion |
| 2016 | 14.40% | 15.16% | 0.69x | 1.38x | Rs931.82 Million |
| 2017 | 13.92% | 17.13% | 0.60x | 1.35x | Rs948.92 Million |
| 2018 | 13.42% | 18.29% | 0.53x | 1.38x | Rs917.50 Million |
| 2019 | 14.25% | 20.61% | 0.53x | 1.31x | Rs1.28 Billion |
| 2020 | 14.99% | 23.66% | 0.49x | 1.30x | Rs1.70 Billion |
| 2021 | 20.79% | 22.21% | 0.69x | 1.36x | Rs2.58 Billion |
| 2022 | 21.39% | 23.46% | 0.67x | 1.36x | Rs3.26 Billion |
| 2023 | 19.45% | 25.73% | 0.61x | 1.25x | Rs3.03 Billion |
| 2024 | 15.33% | 25.14% | 0.52x | 1.18x | Rs1.92 Billion |
| 2025 | 18.20% | 33.65% | 0.46x | 1.16x | Rs3.46 Billion |
| 2026 | 17.19% | 28.67% | 0.51x | 1.17x | Rs3.02 Billion |
Industry Comparison
This section compares Pfizer Limited's net assets metrics with peer companies in the Drug Manufacturers - General industry.
Industry Context
- Industry: Drug Manufacturers - General
- Average net assets among peers: $5,511,252,985
- Average return on equity (ROE) among peers: 25.84%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Pfizer Limited (PFIZER) | Rs42.03 Billion | 13.13% | 0.17x | $2.25 Billion |
| GlaxoSmithKline Pharmaceuticals Limited (GLAXO) | $20.07 Billion | 16.78% | 0.50x | $4.15 Billion |
| NGL Fine-Chem Limited (NGLFINE) | $3.29 Billion | 14.62% | 0.66x | $203.47 Million |
| Sanofi India Limited (SANOFI) | $6.08 Billion | 27.83% | 0.41x | $839.48 Million |
| SANOFI CONS HEALTHC IND L (SANOFICONR) | $2.08 Billion | 79.43% | 0.66x | $1.23 Billion |
| SENORES PHARMACEUTICALS L (SENORES) | $365.90 Million | 2.71% | 0.62x | $655.14 Million |
| TTK Healthcare Limited (TTKHLTCARE) | $1.18 Billion | 13.66% | 1.33x | $134.99 Million |
About Pfizer Limited
Pfizer Limited engages in manufacturing, marketing, trading, and distribution of pharmaceutical products in India and internationally. It offers its products in various therapeutic areas, including neuro/CNS, hormones, cardiovascular, haemophilia, anti-infectives, gynecology, pain/analgesics, orthopedic, oncology, urology, anti-parasitic, gastrointestinal, vaccines, and respiratory, as well as vi… Read more